Kornimate/medical-research-clean huggingface dataset:
correlation between release of cytokines from liver graft and hemodynamic instability

Conditions: Liver Transplantation

Summary: the primary goal of this project is to identify the source of cytokines that are released into circulation during graft reperfusion. seventeen patients scheduled to have adult cadaveric liver transplantation at the milton s. hershey medical center were contacted as prospective participants. blood samples were obtained from the radial artery, the portal vein, and from the graft irrigation. the level of pro-inflammatory cytokines was verified and compared with the amount of catecholamines used to maintain hemodynamic stability.

reperfusion of the graft is the most critical part of liver transplantation because of the difficulties in managing the resulting severe hemodynamic instability. the patients who are accepted to be listed for liver transplantation undergo evaluation of their cardiac function and are usually relatively stable with, at most, minimal cardiac problems (a requirement for inclusion in the liver transplantation program). additionally, we observe completely unpredictable hemodynamic reactions during and after the graft reperfusion, requiring vastly different doses of catecholamine in order to maintain an acceptable level of perfusion pressure. the adverse cardiopulmonary effects are thought to be associated with the preexisting level of various proinflammatory factors, including cytokines (tnf-alpha, il-6) and proinflammatory phospholipase a2 (spla2) produced in the graft as a reaction to the conservation solution and cold temperature (necessary to keep the organ capable for transplantation) and released into the bloodstream during reperfusion. the massive release of cytokines after unclamping of the graft may be responsible for negative inotropy and significant vasodilatation.

Eligibility criteria:
inclusion criteria: * all adult patients scheduled for liver transplantation will be offered the opportunity to participate in this research. exclusion criteria: * patients unable or unwilling to provide adequate informed consent will be excluded.

Keywords: liver failure cytokines hemodynamic instability
high diagnostic performance of the indicator plaster neuropad for the detection of diabetic autonomic neuropathy

Conditions: Diabetic Autonomic Neuropathy; Diabetic Neuropathy

Summary: diabetic autonomic neuropathy (dan) is a prevalent and severe complication of diabetes mellitus (dm). when the autonomic regulation of the cardiovascular system is affected, it is referred to as cardiovascular autonomic neuropathy (can), the most critical subtype of dan. early diagnosis of can is crucial, as it can identify patients at elevated risk for cardiovascular complications. this study aimed to assess the neuropad test's effectiveness, specificity, sensitivity, and accuracy as a diagnostic tool for detecting dan.

diabetic autonomic neuropathy (dan) is a prevalent and severe complication of diabetes mellitus (dm). when the autonomic regulation of the cardiovascular system is affected, it is referred to as cardiovascular autonomic neuropathy (can), the most critical subtype of dan. early diagnosis of can is crucial, as it can identify patients at elevated risk for cardiovascular complications. this study aimed to assess the neuropad test's effectiveness, specificity, sensitivity, and accuracy as a diagnostic tool for detecting dan.

Eligibility criteria:
inclusion criteria: * diabetes mellitus exclusion criteria: * age\>75 years, * estimated creatinine clearance rate (using the cockcroft-gault formula) \<30 ml/ min, * history of limp amputation, * causes of neuropathy other than diabetes, * drugs that can affect perspiration, and * skin disorders that could affect the result.

Keywords: diabetic neuropathy neuropad
effect of mirror therapy and task oriented training for persons with paretic upper extremity

Conditions: Stroke; Cerebrovascular Accident

Summary: the purpose of the study is to determine the effect of a combined mirror therapy and task oriented/repetitive task training on upper extremity function of persons with hemiplegia due to cerebrovascular accident or stroke.

this case series was designed to to determine the effect of a mirror therapy and repetitive task training program on the weak arm and hand functioning due to the consequences of stroke. mirror therapy is a type of therapy mirror reflection of the stronger arm and hand helps to promote reorganization of neurons. studies have shown that mirror therapy is an effective adjunct to regular exercise and task-oriented therapy. to qualify for this study, participants must meet the following criteria: 1) age 21 years or more; 2) first-time stroke with onset of at least 3 months; 3) slight movement of the weaker arm or /and hand; 3) stable physical and mental health; and 4) mentally capable and competent to make health care-related decisions and carry out a home program. participants were required to come to quinnipiac university - north haven campus to undergo mirror therapy training, in 45-60 minute sessions, twice a week for one month. they were also required to complete pre-testing before and post-testing after the mirror therapy program. in addition, they were required to carry-out a home program that includes the use of a mirror box and self-selected tasks. the home program required them to exercise and practice the use of their more affected arm and hand for at least 1-2 hours a day. participation was strictly voluntary. participants were informed of the minimal risks involved as well as their options to continue or withdraw from the study upon initial consent. the study did not yield physical or mental harm to the participants.

Eligibility criteria:
inclusion criteria: * able to give consent, complete home program * minimal arm and hand use with the paretic limb * onset of stroke of at least 3 months exclusion criteria: * \>1 stroke episode * significant cognitive and visual perceptual deficit * lack of social support
case-control viramune (nevirapine) toxicogenomics study

Conditions: HIV Infections

Summary: attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.


Eligibility criteria:
inclusion criteria: inclusion for case 1. male or female patients \>=18 years of age with hiv-1 infection who experienced one or more of the following adverse reactions within the first 8 weeks of starting nevirapine therapy: * grade 3 or 4 lft elevation (alt or ast \> 5x uln) and any symptom consistent with clinical hepatitis (see appendix 10.1) * acute liver failure secondary to nevirapine therapy\* * functional group iii or iv rash * \*acute liver failure is defined as serious liver injury usually requiring hospitalization that may lead to death or liver transplantation. inclusion for control 2. male or female patients \>=18 years of age with hiv-1 infection who have been exposed to nevirapine therapy for at least 18 weeks and who do not meet any of the case inclusion criteria exclusion criteria: exclusion for cases 1. patients with any hepatotoxicity or rash event which in the investigators judgement is not related to nevirapine use (ex. hepatotoxicity due to alcohol or other medicinal use or rash due to other medicinal use). 2. patients who began abacavir or tmp-smx (trimethoprim/sulfamethoxazole) therapy 2 weeks or less prior to or up to 8 weeks after initiating nevirapine therapy. 3. patients with ast or alt elevations \> 5 times the uln (\>= grade 3) just prior to the initiation of nevirapine therapy. exclusion for controls 4. patients who discontinued nevirapine before completing 18 weeks of dosing with 200 mg/day for 2 weeks followed by 400 mg/day thereafter. 5. patients who developed functional group i, iia or iib rash within 18 weeks of starting nevirapine therapy, or any dermatologic condition that could plausibly be attributed to nevirapine. 6. patients with alt or ast elevations \>2.5 x uln (\>grade 1) within 18 weeks of starting nevirapine therapy. 7. any hepatobiliary adverse event that could possibly be attributed to nevirapine. 8. patients who develop any systemic reaction attributable to nevirapine use during the first 18 weeks of nevirapine treatment such as flu-like symptoms, arthralgia, myalgia, or conjunctivitis. exclusion for cases and controls 9. patients who have participated in the 2nn-long-term follow-up study (1100.1454) 10. patients with cd4 count 150 cells/mm3 prior to the initiation of nevirapine therapy (last available result measured 6 months prior to the initiation of nevirapine therapy). 11. evidence of acute co-infection with viral hepatitis. 12. patients taking prednisone, prednisolone, or immuno-modulatory medication within the first 8 weeks of nevirapine therapy. 13. patients who are unwilling to provide blood samples for dna testing. 14. patients who did not sign informed consent and or authorization to release protected health information per local requirements. 15. patients without available liv
efficacy of ivermectin in adult patients with early stages of covid-19 (epic trial)

Conditions: COVID-19

Summary: double blind, placebo controlled, randomized clinical trial to evaluate the efficacy of ivermectin in preventing progression of disease in adult patients with early stages of covid-19


Eligibility criteria:
inclusion criteria: * at least 18 years of age * confirmed sars-cov-2 by rt-pcr or antigen detection in a colombian nih-approved laboratory * beginning of symptoms in the past 7 days * mild disease * informed consent exclusion criteria: * preexisting liver disease * hypersensitivity to ivermectin * participants in other clinical trials for therapies against covid-19 * severe pneumonia * pregnant or breastfeeding women * concomitant use of warfarin, erdafitinib or quinidine * use of ivermectin in the 5 days prior to randomization * inability to obtain a blood sample needed to assess liver transaminases * elevation of transaminases \>1.5 times the normal level * participant whose first contact with the study personnel occurs between days 5 and 7 and at that time manifests significant and progressive resolution of covid-19 related signs and symptoms
nuts for the prevention of cardiovascular disease in chinese adults

Conditions: Cardiovascular Diseases; Dyslipidemias

Summary: this study evaluates the feasibility of walnuts supplementation among population of high cvd risks over a period of 6 months. 70 participants will be controls receiving non-edible gifts. 70 participants will be given 30 grams of walnuts everyday and 70 participants will be given 60 grams of walnuts a day.

increased consumption of nuts improves the levels of lipid risk factors associated with cardiovascular disease and consistently relates to lower risk of cardiovascular disease (cvd) in prospective cohort studies. the estimates of health effects and potential population benefits of increased consumption of nuts are based mostly on observational data and there remains considerable uncertainty about whether higher intake of nuts will actually reduce cardiovascular outcomes. to address this uncertainty will require a well-conducted, adequately powered, large-scale, randomised control trial that tests the causal relationship between nut intake and the risk of cardiovascular diseases. we hereby designed a 6-month walnut supplementation trial in a rural area of china with high rates of cvd, to obtain data to support and help to refine the design of a future long-term large rct testing the effect of nut supplementation on cvd risk. the main objectives of the current trial are to assess the acceptability and adherence to two different doses of walnut supplementation (30 and 60 grams per day). the exploratory objectives are to determine the effects of walnut supplementation on cardiovascular risk factors including blood lipids, fasting glucose, and body weight.

Eligibility criteria:
inclusion criteria: 1. a history of cvd, defined on the basis of a prior hospitalisation for a myocardial infarction or stroke, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (with or without stenting), peripheral revascularization (angioplasty or surgery), symptomatic with documented hemodynamically-significant carotid or peripheral vascular disease, or amputation secondary to vascular disease, or 2. male aged \>60 years, or female aged\>65 years, and with at least two of the following risk factors: 1. type 2 diabetes requiring treatment with at least two oral anti-hyperglycaemic agents and/or insulin 2. systolic blood pressure \> 140 mmhg while on one or more antihypertensive agents 3. current daily smoking 4. dyslipidaemia defined as hdl-cholesterol\ 6.0mmol/l 5. micro or macro albuminuria exclusion criteria: 1. allergic to nuts (history of food allergy with hypersensitivity to any of the components of nuts) 2. other serious medical condition that prevents nut consumption (e.g. digestive disease with fat intolerance) 3. any medical condition thought to limit survival to less than 1 year 4. difficulty with consuming nuts (e.g. dental health issues that prevent chewing walnuts) 5. unwilling to consume nuts

Keywords: alpha linolenic acid
bay 59-7939 (xarelto, spaf), non interventional studies

Conditions: Atrial Fibrillation

Summary: according to recent guidelines, long-term anticoagulation is recommended for patients with atrial fibrillation (af) and a risk profile with cha2ds2-vasc score of 1 or more. vitamin k antagonists(vak) and novel oral anticoagulants such as rivaroxaban are current treatment options for af patients with additional risk factors for stroke. currently there are only limited information to what extend af patients prefer one or the other treatment option based on patient relevant characteristics of novel oral anticoagulants vs. vkas. it is also unknown which of the characteristics influences patient preference most and how this relates to a neutral comparator. furthermore, an additional unknown factor is also how patient evaluate their current treatment and if this leads to differences among treatment with vkas and rivaroxaban.


Eligibility criteria:
inclusion criteria: a.general criteria (group 1and group2): * diagnosed non-valvular af * older than 18 years * general capability and willingness to perform a structured patient interview in german * no participation in any other clinical or observational study over the last 3 month additional criteria for group1 (vka-experienced): * active vka-therapy for at least 3 month without significant interruptions * in case of perioperative interruption vka treatment should not have been hold for more than two weeks. additional criteria for group2 (rivaroxaban-experienced patients): * active rivaroxaban-therapy for at least 3 month without significant interruptions * in case of perioperative interruption vka treatment should not have been hold for more than two weeks. exclusion criteria: * participation in any other clinical or observational study over the last 3 month
colchicine versus ruxolitinib and secukinumab in open-label prospective randomized trial in patients with covid-19

Conditions: COVID 19

Summary: patients with mild and severe coronavirus disease 2019 (covid 19) will be randomized 3:1:1:3 into four groups: colchicine, ruxolitinib, secukinumab, and control groups. . patients will be follow-up during 45 days after randomization. change in clinical assessment score covid 19 (cas covid 19) between baseline and 12th day will be evaluated as the primary endpoint. risk of death or mechanical ventilation during 45 days after randomization will also be assessed


Eligibility criteria:
inclusion criteria: * signed inform consent * covid 19 with the mild and severe course. the diagnosis could be made with positive polymerase chain reaction (pcr) (international statistical classification (icd-10) code - u07.1) and/or virus pneumonia in computer tomography (icd 10 code - u07.2) * lung exposure on ct more than 25% * sp02 without supportive oxygen ≤ 93% * c-reactive protein \> 60 mg/l or elevation of c reactive protein 3 times in 8-14 days after first symptoms exclusion criteria: * pregnancy and breastfeeding * hypersensitivity to colchicine * hypersensitivity to ruxolitinib * hypersensitivity to secukinumab * known liver failure * glomerular filtration rate \<20 ml/ min * physician judgment that the patient will need mechanical ventilation in 24 hours * qtc \> 450 ms * other indications for to colchicine, ruxolitinib, and secukinumab * chronic therapy with corticosteroids or immunosuppressive therapy * active cancer

Keywords: covid 19 colchicine ruxolitinib secukinumab
efficacy study of va106483 in males with nocturia.

Conditions: Nocturia

Summary: to investigate the effect of va106483 on nocturia related clinical outcomes compared to placebo.

nocturia, defined as waking to urinate at least once per night between periods of sleep, is a common complaint which increases with age. va106483 is a non-peptide drug va106483 that is being developed for the treatment of nocturia in males. the purpose of this study is to investigate the effect of va106483 on the number of times the subject needs to get up to urinate (nocturnal void) per night and to determine the effect on the time between the subject's bedtime and the time they first wake up to urinate.

Eligibility criteria:
inclusion criteria: * male subjects aged ≥18 years (no upper limit) with nocturia * generally well (concomitant illness/conditions well controlled) * serum sodium within the normal limits * normal or not clinically significant prostate specific antigen levels * able to comply with the requirements of the study * provide written informed consent exclusion criteria: * prostatic cancer * signs or symptoms of heart failure * peripheral pitting oedema extending ≥10 cm above the ankle * palpable bladder or pelvic mass on abdominal examination * enuresis or night-time incontinence * excessive nocturnal void frequency * sleep disorders * diabetes insipidus or uncontrolled diabetes mellitus * presence of blood or glucose in the urine on urinalysis that is clinically significant * urinary tract infection * polydipsia * syndrome of inappropriate antidiuretic hormone secretion * body mass index ≥35 * high calcium levels or low potassium levels * other protocol defined eligibility criteria may apply

Keywords: va106483 nocturia males nocturnal voids anti-diuretic hyponatraemia
zonisamide in the treatment of essential tremor

Conditions: Essential Tremor

Summary: the purpose of this study is to determine if zonisamide is effective in reducing tremors in patients with essential tremor.

the subjects will remain on their usual medication and a baseline assessment using the fahn tolosa marin tremor rating scale will be performed and will be video taped.

Eligibility criteria:
inclusion criteria: 1. diagnosis of essential tremor based on the tremor investigational group criteria for definite or probable essential tremor. 2. age: 18 years or over. 3. willingness and ability to comply with the study requirements and give informed consent. exclusion criteria: 1. known history of psychiatric disorder, major depression, dementia, aplastic anemia, or stevens-johnson syndrome. 2. known alcohol or substance abuse in previous 12 months. 3. positive pregnancy test. 4. unwillingness to use adequate contraceptive methods if of childbearing potential. 5. known allergy to sulfonamides. 6. laboratory abnormalities prior to onset of trial.

Keywords: et
extracorporeal shockwave myocardial revascularization in refractory angina

Conditions: Angina Refractory; Angina Pectoris

Summary: this is a prospective cohort study to examine the efficacy of esmr application in patients with refractory angina despite optimal medical therapy, not suitable for further pci or cabg. characteristics such as angina class scores (ccs class score), nitroglycerin consumption and hospitalization were compared at baseline and 1, 6 and 12 months after esmr therapy. the effect on cardiac perfusion was assessed at 6 months.


Eligibility criteria:
inclusion criteria: * history of coronary artery disease; * refractory angina pectoris, defined as the persistence of a angina pectoris (canadian cardiovascular society class ≥ 2) for more than 3 months, despite the use of optimal medical therapy (which included β blockers, calcium channel blockers, long-acting nitrates, ivabradine, ranolazine and trimetazidine, up-titrated to the maximal tolerated dose) and coronary disease not amenable for further revascularization (as determined by an interventional cardiologist and cardiac surgeon); * stable maximal medical therapy for at least 6 weeks; * stress-induced ischemia at baseline spect; * left ventricular ejection fraction higher than 40%; * age higher than 18 years. exclusion criteria: * myocardial infarction or unstable angina in the previous 3 months, * acute myocarditis, pericarditis, left ventricular thrombus, cardiac malignancies, chronic pulmonary disease (including emphysema and pulmonary fibrosis), endocarditis * pregnancy
experimental overfeeding in humans

Conditions: Overfed; Obesity

Summary: the objective of this study is to determine the homeostatic mechanisms that counteract weight gain in response to experimental overfeeding.

the homeostatic regulation of body weight implies that biological processes have evolved to protect energy stores from changes to the food environment. accordingly, many individuals remain remarkably weight stable over years without carefully considering how much they eat or how much energy they expend, which has given rise to the theory that body weight is regulated around an individual biological 'set point'. notably, overfeeding humans in experimentally controlled conditions, support this phenomenon, but the underlying mechanisms are unknown. to systematically map out the components of the overfed state, the investigators will execute a 2-week randomized controlled overfeeding trial in lean and overweight individuals. the trial is preceded by a 1-week lead-in period and followed by a 2-wk controlled ad libitum study period. the comparison between lean and overweight subjects, men and women, enables the determination of whether a differential response in overfeeding-induced signals is present in relation to bmi and sex.

Eligibility criteria:
inclusion criteria: * male or female otherwise healthy subjects * 20-40 years of age * bmi (body mass index) between 22-30 kg/m2 exclusion criteria: * present or previous cardiovascular disease, diabetes or thyroid-disease * smoking * more than 3 hours of planned physical activity per week
validation of dragon versus a simplified dragon/machine learning

Conditions: Stroke, Acute

Summary: the ct-dragon score can predict long-term functional outcome after acute stroke treated by thrombolysis. however, implementation in clinical practice is hampered by a lack of validation in the broad spectrum of stroke patients undergoing thrombectomy, whether or not in combination with thrombolysis or conservative treatment. furthermore, the ct-dragon score considers multiple items, which are not always readily available in every setting. this study aims to investigate whether either a simplified version of the ct-dragon score with only three clinical items or a machine learning technique could be as powerful and more feasible.

the investigators aim to validate the ct-dragon score in all ischaemic stroke localisations and for all treatment options, including a conservative treatment policy. the predictability will then be compared with on the one hand simplified prognostic models that include only a selective set of highly predictive parameters that have already been described in the literature, such as patient age, national institutes of health stroke scale (nihss) and pre-stroke modified rankin scale (mrs). on the other hand, machine learning techniques, that incorporate a large set of variables and have recently shown some promising results, will also be applied to predict long-term outcome after ischaemic stroke.

Eligibility criteria:
inclusion criteria: * all patients diagnosed with a stroke exclusion criteria: -

Keywords: ct-dragon score